Farabi Pharmaceutical (XTEH:DFRB1) Goodwill: IRR0.00 Mil (As of . 20)


What is Farabi Pharmaceutical Goodwill?

Farabi Pharmaceutical XTEH:DFRB1 Goodwill is IRR0.00 Mil as of . 20.

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Farabi Pharmaceutical's goodwill for the quarter that ended in . 20 was IRR0.00 Mil.

Farabi Pharmaceutical  (XTEH:DFRB1) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Farabi Pharmaceutical's Goodwill-to-Asset Ratio for the fiscal year that ended in . 20 is calculated as

Goodwill-to-Asset (A: . 20 )=Goodwill/Total Assets
=/
=

Farabi Pharmaceutical's Goodwill-to-Asset Ratio for the quarter that ended in . 20 is calculated as

Goodwill-to-Asset (Q: . 20 )=Goodwill/Total Assets
=/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.

Farabi Pharmaceutical Goodwill Related Terms

Farabi Pharmaceutical Goodwill Historical Data

* Premium members only.

The historical data trend for Farabi Pharmaceutical's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farabi Pharmaceutical Goodwill Chart

Farabi Pharmaceutical Annual Data
Trend
Goodwill

Farabi Pharmaceutical Quarterly Data
Goodwill

Farabi Pharmaceutical Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.

Frequently Asked Questions Learn more about Goodwill →
What does a Goodwill of IRR0.00 Mil mean?
Farabi Pharmaceutical (XTEH:DFRB1) has a Goodwill of IRR0.00 Mil as of . 20. Goodwill is the intangible assets representing the value in excess of the acquired company's value. View historical data on Farabi Pharmaceutical and its competitors.
Is Farabi Pharmaceutical's Goodwill too high?
Farabi Pharmaceutical's current Goodwill is IRR0.00 Mil.
How does Farabi Pharmaceutical's Goodwill compare to IMNPQ and INNV?
Farabi Pharmaceutical's Goodwill of IRR0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Goodwill for a Drug Manufacturers company?
A good Goodwill depends on the Drug Manufacturers industry context. However, Goodwill should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Goodwill mean?
A high Goodwill can signal that a stock is expensive relative to its fundamentals. Goodwill is the intangible assets representing the value in excess of the acquired company's value. View historical data on Farabi Pharmaceutical and its competitors. Farabi Pharmaceutical's current Goodwill is IRR0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farabi Pharmaceutical stock overvalued right now?
Farabi Pharmaceutical (XTEH:DFRB1) has a current Goodwill of IRR0.00 Mil. The current Goodwill is IRR0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Goodwill calculated?
Goodwill is calculated from a company's financial statements. For Farabi Pharmaceutical (XTEH:DFRB1), the current Goodwill is IRR0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Farabi Pharmaceutical Business Description

Address South Kheradmand, No. 45, First Floor, Tehran, IRN, 1584853114
Farabi Pharmaceutical is a pharmaceutical company based in Iran. It produces various oral antibiotic-related and non-antibiotic products and dietary supplements. The company develops anti-migraine, antivirals, cholesterol, diabetic, cardiovascular, gastrointestinal, neuroleptics, anti-prostatic and anti-inflammatory and pain release drugs. It offers products in the form of tablet, capsule and suspensions which include Amoxicillin, Cefixime, Azithromycin, Ciprofloxacin, Nitroglycerin, Repaglinide, Orlistat, Domperidone, among others.